drugset / Trial / NCT03552796
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein (sEphB4-HSA), and to see how well it works in treating participants with bladder cancer that has come back or that isn't responding to bacillus Calmette-Guerin (BCG) vaccine treatment. sEphB4-HAS prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. Giving sEphB4-HSA may work better in treating participants with bladder cancer.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2024-08-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sEphB4-HSA | Protein / enzyme biologic | 25 mg | Other |
| Subject | sEphB4-HSA | Protein / enzyme biologic | 50 mg | Other |
| Subject | sEphB4-HSA | Protein / enzyme biologic | 75 mg | Other |
| Subject | sEphB4-HSA | Protein / enzyme biologic | 100 mg | Other |
| Subject | sEphB4-HSA | Protein / enzyme biologic | 125 mg | Other |